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esis of the disease as well as prolonged prior exposure to cytotoxic
chemotherapy and immune suppression. Clinical approaches to im-
prove outcomes should optimize disease control while minimizing
toxicity before and after transplant.302
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Allogeneic marrow transplantation offers curative therapy for
pediatric patients with severe aplastic anemia. Over the past 4 de-
cades, significant improvements in the long term outcome of pa-
tients treated with allogeneic marrow grafts have resulted from
progress in the prevention and treatment of graft rejection and
graft-versus-host disease (GVHD). Here we report the outcome
of 149 pediatric patients, ages 2-19 years who received HLA-
matched related marrow grafts for treatment of severe aplastic ane-
mia between 1971 and 2009. Patients were divided into 3 groups,
reflecting changes in conditioning and GVHD prophylaxis regi-
mens that occurred over time. Group 1 consisted of 100 patients
who were conditioned with Cyclophosphamide (CY; 200 mg/kg)
followed by ‘‘long’’ (102 days) Methotrexate (MTX) for GVHD
prevention. Group 2 consisted of 19 patients who received CY fol-
lowed by ‘‘short’’ (days 1, 3, 6, and 11) MTX and cyclosporine
(CSP; through day 180). Group 3 consisted of 30 patients who
were conditioned with CY and horse antithymocyte globulin
(ATG) followed by MTX and CSP for GVHD prevention. The
risk of mortality was significantly different between the 3 groups
(p\0.0001).With a median follow up of 25.2 (range, 0.3-37) years,
the 5-year survival estimates were 66% for group 1, 95% for group
2, and 100% for group 3. There was a suggestion that the risk of re-
jection was different between the 3 groups (p5 0.06) and the 3-year
estimates of graft rejection were 22%, 32%, and 12%, respectively.
The estimated probabilities of grades III-IV acute GVHD were
15% for group 1, 0% for group 2, and 3% for group 3. The
2-year estimates of chronic GVHD were 21%, 21%, and 7%,
respectively. In summary, advances in conditioning and GVHD
prophylaxis regimens as well as supportive care during the past 39
years have led to improved outcomes for pediatric patients with
severe aplastic anemia. These results strongly support the use of
allogeneic marrow transplantation for newly diagnosed pediatric
patients with severe aplastic anemia who have an HLA-matched
related donor.303
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Disseminated or relapsed pediatric solid tumors usually have dis-
mal prognosis and HSCT has been used as a treatment option for
children with chemo-sensitive tumors. With modern intensive pro-
tocols, patients usually have been treated with many different drugs
and may have some degree of renal or cardiac compromise. One in-
teresting alternative would be to use two alkylating agents, busulfan
and melphalan: these drugs are not used in pediatric chemotherapy
protocols, their most important dose-limiting toxicity is marrow
suppression, and they are not toxic to the heart or kidneys. Our ob-
jective is to describe the institutional experience with autologous
HSCTwith busulfan-melphalan for the treatment of relapsed or dis-
seminated pediatric solid tumors.
Results: Nineteen patients with a median age of 11 years (2-33), 10
male, were transplanted, 12/19 with measurable disease. Diagnoses
were alveolar sarcoma (1), desmoplastic small round cell tumor
(DSRCT, 1), Wilms tumor (1), primitive neuroectodermal tumor
(PNET, 2), synovial sarcoma (2), Ewing sarcoma (6, all but 1 with
advanced disease), and stage-4 neuroblastoma (6, only 1 in 1st remis-
sion). All patients had normal marrow aspirate and biopsy prior to
transplant, including immunocytochemistry. Conditioning therapy
was busulfan 1 mg/kg/dose q 6 hours PO for 4 days on D-5 to D-
2 and melphalan 140 mg/m2 IV on D-1. Local irradiation, when
planned, was postponed for the post transplant period. Three re-
ceived bone marrow grafts and 16 peripheral blood stem cells with
target cell dose of 5x106 CD34 cells/kg. All patients engrafted
promptly and none of them had severe toxicities. One had late sinu-
soidal obstruction syndrome and one Ewing sarcoma patient had
Guillain Barre Syndrome at the time of post HSCT irradiation to
his leg. One patient with PNET, the patient with DSRCT, Wilms
tumor and 3/6 with Ewing sarcoma died of their primary disease af-
ter a median of 320 days post HSCT. The patient with alveolar sar-
coma, both with synovial sarcoma, 3 with Ewing sarcoma and all
neuroblastoma patients remain in remission and well after a median
of 10.5 months post transplant (2-119). In conclusion, busulfan-mel-
phalan was very well tolerated and 13/19 patients with advanced tu-
mors remain well and in remission. Longer follow up and a larger
number of patients are needed to define the – promising – role of
this preparative regime for high dose chemotherapy and HSCT in
the treatment of relapsed or disseminated solid tumors.304
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Among 650 patients transplanted in our institution between 1992
and 2008, 19 (3%) are known to have developed a SMNpost-HSCT.
We have studied HSCT survivors who developed exostoses. We
identified 27 patients with clinical and/or radiologic exostoses trans-
planted between 3/1992 and 12/2003. One patient with exostosis had
co-existent malignancies and was treated elsewhere so was excluded
from all analyses due to incomplete data and the possibility of a ge-
netic cancer susceptibility. This group was compared to controls that
were matched for gender, age within 3 years and on same side of pu-
berty, malignancy/not and HSCT type. Our aim is to describe
whether the exostosis patients have a higher risk for developing
SMNs post-HSCT. There were 6/26 (23%) with SMNs in the exos-
tosis group, 4/26 (15%) in the control group (McNemar p-valueAge at first HSCT Time HSCT to SMN A/C GvHD
Mean (range) Mean (range) %
5.5y (0.5-9.1) 11.3y (6.6-16.1) AGvHD 17%
CGvHD 50%
4.9y (1.4-9.1) 9.0y (4.3-13.3) AGvHD 75%
CGvHD 25%
